0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Gestational Trophoblastic Disease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: December 2024
|
Report Code: QYRE-Auto-9Y12727
Home | Market Reports | Health| Reproductive Health
Global Gestational Trophoblastic Disease Market Research Report 2022
BUY CHAPTERS

Gestational Trophoblastic Disease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-9Y12727
Report
December 2024
Pages:104
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Gestational Trophoblastic Disease - Market Size

The global market for Gestational Trophoblastic Disease was estimated to be worth US$ 1940 million in 2023 and is forecast to a readjusted size of US$ 2587.6 million by 2030 with a CAGR of 4.3% during the forecast period 2024-2030

Gestational Trophoblastic Disease - Market

Gestational Trophoblastic Disease - Market

Gestational trophoblastic disease (GTD) is a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception. In gestational trophoblastic disease (GTD), a tumor develops inside the uterus from tissue that forms after conception (the joining of sperm and egg).
The global gestational trophoblastic disease (GTD) market refers to the market for diagnostic tests, treatments, and management strategies aimed at addressing GTD, a group of rare tumors that arise in the cells of the placenta during pregnancy. GTD includes conditions such as hydatidiform mole, gestational trophoblastic neoplasia, and choriocarcinoma.
The market for GTD is driven by several factors, including the increasing incidence of these diseases, advancements in diagnostic techniques, and improvements in treatment options. Early detection and accurate diagnosis are crucial for effective management of GTD. Diagnostic methods include ultrasound, human chorionic gonadotropin (hCG) measurement, and histopathological examination.
The primary treatment for GTD is the surgical removal of the affected tissue, which is often followed by chemotherapy in cases of gestational trophoblastic neoplasia and choriocarcinoma. Methotrexate is commonly used as a chemotherapy drug, and other chemotherapeutic agents may also be employed depending on the stage and type of the disease. In cases of high-risk or resistant GTD, additional treatments such as radiation therapy may be recommended.
Geographically, North America and Europe hold a significant share in the global GTD market, primarily due to factors such as well-established healthcare infrastructure, advanced diagnostic technologies, and increased awareness about GTD. Asia-Pacific is also experiencing growth in the GTD market, attributed to factors such as rising healthcare expenditure, improving healthcare infrastructure, and increasing awareness about women’s health.
Key players in the global GTD market include pharmaceutical companies, diagnostic test manufacturers, and healthcare providers specializing in women’s health. These companies focus on developing innovative diagnostic tests, drugs, and treatment protocols to improve patient outcomes and ensure better management of GTD.
However, challenges in the GTD market include the rarity of these diseases, leading to limited awareness and expertise among healthcare professionals, as well as the potential for complications and the need for individualized treatment approaches. Additionally, the emotional and psychological impact of GTD on patients and their families is an area that requires attention and support.
In summary, the global gestational trophoblastic disease market is driven by factors such as the increasing incidence of these rare tumors, advancements in diagnostic techniques, and improvements in treatment options. North America and Europe currently lead the market, but Asia-Pacific is witnessing growth. Key players in the market continue to invest in research and development to improve diagnostic accuracy, develop targeted therapies, and ensure optimal management of GTD.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Gestational Trophoblastic Disease, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gestational Trophoblastic Disease by region & country, by Type, and by Application.
The Gestational Trophoblastic Disease market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gestational Trophoblastic Disease.
Market Segmentation

Scope of Gestational Trophoblastic Disease - Market Report

Report Metric Details
Report Name Gestational Trophoblastic Disease - Market
Forecasted market size in 2030 US$ 2587.6 million
CAGR 4.3%
Forecasted years 2024 - 2030
Segment by Type:
  • Chemotherapy
  • Surgery
  • Radiation Therapy
  • Others
Segment by Application
  • Hospitals
  • Clinics
  • Cancer Research Institutes
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bristol Myers Squibb, Antares Pharma, Novartis AG, Accord Healthcare Limited, Eli Lilly and Company, Sanofi, Bayer AG, Amgen, Merck KGaA, Teva Pharmaceuticals, B.P Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Gestational Trophoblastic Disease manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Gestational Trophoblastic Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Gestational Trophoblastic Disease in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Gestational Trophoblastic Disease - Market size in 2030?

Ans: The Gestational Trophoblastic Disease - Market size in 2030 will be US$ 2587.6 million.

Who are the main players in the Gestational Trophoblastic Disease - Market report?

Ans: The main players in the Gestational Trophoblastic Disease - Market are Bristol Myers Squibb, Antares Pharma, Novartis AG, Accord Healthcare Limited, Eli Lilly and Company, Sanofi, Bayer AG, Amgen, Merck KGaA, Teva Pharmaceuticals, B.P Pharma

What are the Application segmentation covered in the Gestational Trophoblastic Disease - Market report?

Ans: The Applications covered in the Gestational Trophoblastic Disease - Market report are Hospitals, Clinics, Cancer Research Institutes, Others

What are the Type segmentation covered in the Gestational Trophoblastic Disease - Market report?

Ans: The Types covered in the Gestational Trophoblastic Disease - Market report are Chemotherapy, Surgery, Radiation Therapy, Others

Recommended Reports

Gynecological Diseases

Women's Health Diagnostics

Rare & Cancer Diseases

1 Market Overview
1.1 Gestational Trophoblastic Disease Product Introduction
1.2 Global Gestational Trophoblastic Disease Market Size Forecast
1.3 Gestational Trophoblastic Disease Market Trends & Drivers
1.3.1 Gestational Trophoblastic Disease Industry Trends
1.3.2 Gestational Trophoblastic Disease Market Drivers & Opportunity
1.3.3 Gestational Trophoblastic Disease Market Challenges
1.3.4 Gestational Trophoblastic Disease Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Gestational Trophoblastic Disease Players Revenue Ranking (2023)
2.2 Global Gestational Trophoblastic Disease Revenue by Company (2019-2024)
2.3 Key Companies Gestational Trophoblastic Disease Manufacturing Base Distribution and Headquarters
2.4 Key Companies Gestational Trophoblastic Disease Product Offered
2.5 Key Companies Time to Begin Mass Production of Gestational Trophoblastic Disease
2.6 Gestational Trophoblastic Disease Market Competitive Analysis
2.6.1 Gestational Trophoblastic Disease Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Gestational Trophoblastic Disease Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gestational Trophoblastic Disease as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Chemotherapy
3.1.2 Surgery
3.1.3 Radiation Therapy
3.1.4 Others
3.2 Global Gestational Trophoblastic Disease Sales Value by Type
3.2.1 Global Gestational Trophoblastic Disease Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Gestational Trophoblastic Disease Sales Value, by Type (2019-2030)
3.2.3 Global Gestational Trophoblastic Disease Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Cancer Research Institutes
4.1.4 Others
4.2 Global Gestational Trophoblastic Disease Sales Value by Application
4.2.1 Global Gestational Trophoblastic Disease Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Gestational Trophoblastic Disease Sales Value, by Application (2019-2030)
4.2.3 Global Gestational Trophoblastic Disease Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Gestational Trophoblastic Disease Sales Value by Region
5.1.1 Global Gestational Trophoblastic Disease Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Gestational Trophoblastic Disease Sales Value by Region (2019-2024)
5.1.3 Global Gestational Trophoblastic Disease Sales Value by Region (2025-2030)
5.1.4 Global Gestational Trophoblastic Disease Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Gestational Trophoblastic Disease Sales Value, 2019-2030
5.2.2 North America Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Gestational Trophoblastic Disease Sales Value, 2019-2030
5.3.2 Europe Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Gestational Trophoblastic Disease Sales Value, 2019-2030
5.4.2 Asia Pacific Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Gestational Trophoblastic Disease Sales Value, 2019-2030
5.5.2 South America Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Gestational Trophoblastic Disease Sales Value, 2019-2030
5.6.2 Middle East & Africa Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Gestational Trophoblastic Disease Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Gestational Trophoblastic Disease Sales Value
6.3 United States
6.3.1 United States Gestational Trophoblastic Disease Sales Value, 2019-2030
6.3.2 United States Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Gestational Trophoblastic Disease Sales Value, 2019-2030
6.4.2 Europe Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Gestational Trophoblastic Disease Sales Value, 2019-2030
6.5.2 China Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.5.3 China Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Gestational Trophoblastic Disease Sales Value, 2019-2030
6.6.2 Japan Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Gestational Trophoblastic Disease Sales Value, 2019-2030
6.7.2 South Korea Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Gestational Trophoblastic Disease Sales Value, 2019-2030
6.8.2 Southeast Asia Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Gestational Trophoblastic Disease Sales Value, 2019-2030
6.9.2 India Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.9.3 India Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bristol Myers Squibb
7.1.1 Bristol Myers Squibb Profile
7.1.2 Bristol Myers Squibb Main Business
7.1.3 Bristol Myers Squibb Gestational Trophoblastic Disease Products, Services and Solutions
7.1.4 Bristol Myers Squibb Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.1.5 Bristol Myers Squibb Recent Developments
7.2 Antares Pharma
7.2.1 Antares Pharma Profile
7.2.2 Antares Pharma Main Business
7.2.3 Antares Pharma Gestational Trophoblastic Disease Products, Services and Solutions
7.2.4 Antares Pharma Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.2.5 Antares Pharma Recent Developments
7.3 Novartis AG
7.3.1 Novartis AG Profile
7.3.2 Novartis AG Main Business
7.3.3 Novartis AG Gestational Trophoblastic Disease Products, Services and Solutions
7.3.4 Novartis AG Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.3.5 Accord Healthcare Limited Recent Developments
7.4 Accord Healthcare Limited
7.4.1 Accord Healthcare Limited Profile
7.4.2 Accord Healthcare Limited Main Business
7.4.3 Accord Healthcare Limited Gestational Trophoblastic Disease Products, Services and Solutions
7.4.4 Accord Healthcare Limited Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.4.5 Accord Healthcare Limited Recent Developments
7.5 Eli Lilly and Company
7.5.1 Eli Lilly and Company Profile
7.5.2 Eli Lilly and Company Main Business
7.5.3 Eli Lilly and Company Gestational Trophoblastic Disease Products, Services and Solutions
7.5.4 Eli Lilly and Company Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.5.5 Eli Lilly and Company Recent Developments
7.6 Sanofi
7.6.1 Sanofi Profile
7.6.2 Sanofi Main Business
7.6.3 Sanofi Gestational Trophoblastic Disease Products, Services and Solutions
7.6.4 Sanofi Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.6.5 Sanofi Recent Developments
7.7 Bayer AG
7.7.1 Bayer AG Profile
7.7.2 Bayer AG Main Business
7.7.3 Bayer AG Gestational Trophoblastic Disease Products, Services and Solutions
7.7.4 Bayer AG Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.7.5 Bayer AG Recent Developments
7.8 Amgen
7.8.1 Amgen Profile
7.8.2 Amgen Main Business
7.8.3 Amgen Gestational Trophoblastic Disease Products, Services and Solutions
7.8.4 Amgen Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.8.5 Amgen Recent Developments
7.9 Merck KGaA
7.9.1 Merck KGaA Profile
7.9.2 Merck KGaA Main Business
7.9.3 Merck KGaA Gestational Trophoblastic Disease Products, Services and Solutions
7.9.4 Merck KGaA Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.9.5 Merck KGaA Recent Developments
7.10 Teva Pharmaceuticals
7.10.1 Teva Pharmaceuticals Profile
7.10.2 Teva Pharmaceuticals Main Business
7.10.3 Teva Pharmaceuticals Gestational Trophoblastic Disease Products, Services and Solutions
7.10.4 Teva Pharmaceuticals Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.10.5 Teva Pharmaceuticals Recent Developments
7.11 B.P Pharma
7.11.1 B.P Pharma Profile
7.11.2 B.P Pharma Main Business
7.11.3 B.P Pharma Gestational Trophoblastic Disease Products, Services and Solutions
7.11.4 B.P Pharma Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.11.5 B.P Pharma Recent Developments
8 Industry Chain Analysis
8.1 Gestational Trophoblastic Disease Industrial Chain
8.2 Gestational Trophoblastic Disease Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Gestational Trophoblastic Disease Sales Model
8.5.2 Sales Channel
8.5.3 Gestational Trophoblastic Disease Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Gestational Trophoblastic Disease Market Trends
    Table 2. Gestational Trophoblastic Disease Market Drivers & Opportunity
    Table 3. Gestational Trophoblastic Disease Market Challenges
    Table 4. Gestational Trophoblastic Disease Market Restraints
    Table 5. Global Gestational Trophoblastic Disease Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Gestational Trophoblastic Disease Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Gestational Trophoblastic Disease Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Gestational Trophoblastic Disease Product Type
    Table 9. Key Companies Time to Begin Mass Production of Gestational Trophoblastic Disease
    Table 10. Global Gestational Trophoblastic Disease Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gestational Trophoblastic Disease as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Gestational Trophoblastic Disease Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Gestational Trophoblastic Disease Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Gestational Trophoblastic Disease Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Gestational Trophoblastic Disease Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Gestational Trophoblastic Disease Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Gestational Trophoblastic Disease Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Gestational Trophoblastic Disease Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Gestational Trophoblastic Disease Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Gestational Trophoblastic Disease Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Gestational Trophoblastic Disease Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Gestational Trophoblastic Disease Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Gestational Trophoblastic Disease Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Gestational Trophoblastic Disease Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Gestational Trophoblastic Disease Sales Value by Region (2019-2024) & (%)
    Table 27. Global Gestational Trophoblastic Disease Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Gestational Trophoblastic Disease Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Gestational Trophoblastic Disease Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Gestational Trophoblastic Disease Sales Value, (2025-2030) & (US$ Million)
    Table 31. Bristol Myers Squibb Basic Information List
    Table 32. Bristol Myers Squibb Description and Business Overview
    Table 33. Bristol Myers Squibb Gestational Trophoblastic Disease Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of Bristol Myers Squibb (2019-2024)
    Table 35. Bristol Myers Squibb Recent Developments
    Table 36. Antares Pharma Basic Information List
    Table 37. Antares Pharma Description and Business Overview
    Table 38. Antares Pharma Gestational Trophoblastic Disease Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of Antares Pharma (2019-2024)
    Table 40. Antares Pharma Recent Developments
    Table 41. Novartis AG Basic Information List
    Table 42. Novartis AG Description and Business Overview
    Table 43. Novartis AG Gestational Trophoblastic Disease Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of Novartis AG (2019-2024)
    Table 45. Novartis AG Recent Developments
    Table 46. Accord Healthcare Limited Basic Information List
    Table 47. Accord Healthcare Limited Description and Business Overview
    Table 48. Accord Healthcare Limited Gestational Trophoblastic Disease Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of Accord Healthcare Limited (2019-2024)
    Table 50. Accord Healthcare Limited Recent Developments
    Table 51. Eli Lilly and Company Basic Information List
    Table 52. Eli Lilly and Company Description and Business Overview
    Table 53. Eli Lilly and Company Gestational Trophoblastic Disease Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of Eli Lilly and Company (2019-2024)
    Table 55. Eli Lilly and Company Recent Developments
    Table 56. Sanofi Basic Information List
    Table 57. Sanofi Description and Business Overview
    Table 58. Sanofi Gestational Trophoblastic Disease Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of Sanofi (2019-2024)
    Table 60. Sanofi Recent Developments
    Table 61. Bayer AG Basic Information List
    Table 62. Bayer AG Description and Business Overview
    Table 63. Bayer AG Gestational Trophoblastic Disease Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of Bayer AG (2019-2024)
    Table 65. Bayer AG Recent Developments
    Table 66. Amgen Basic Information List
    Table 67. Amgen Description and Business Overview
    Table 68. Amgen Gestational Trophoblastic Disease Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of Amgen (2019-2024)
    Table 70. Amgen Recent Developments
    Table 71. Merck KGaA Basic Information List
    Table 72. Merck KGaA Description and Business Overview
    Table 73. Merck KGaA Gestational Trophoblastic Disease Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of Merck KGaA (2019-2024)
    Table 75. Merck KGaA Recent Developments
    Table 76. Teva Pharmaceuticals Basic Information List
    Table 77. Teva Pharmaceuticals Description and Business Overview
    Table 78. Teva Pharmaceuticals Gestational Trophoblastic Disease Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of Teva Pharmaceuticals (2019-2024)
    Table 80. Teva Pharmaceuticals Recent Developments
    Table 81. B.P Pharma Basic Information List
    Table 82. B.P Pharma Description and Business Overview
    Table 83. B.P Pharma Gestational Trophoblastic Disease Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Gestational Trophoblastic Disease Business of B.P Pharma (2019-2024)
    Table 85. B.P Pharma Recent Developments
    Table 86. Key Raw Materials Lists
    Table 87. Raw Materials Key Suppliers Lists
    Table 88. Gestational Trophoblastic Disease Downstream Customers
    Table 89. Gestational Trophoblastic Disease Distributors List
    Table 90. Research Programs/Design for This Report
    Table 91. Key Data Information from Secondary Sources
    Table 92. Key Data Information from Primary Sources
    Table 93. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Gestational Trophoblastic Disease Product Picture
    Figure 2. Global Gestational Trophoblastic Disease Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Gestational Trophoblastic Disease Sales Value (2019-2030) & (US$ Million)
    Figure 4. Gestational Trophoblastic Disease Report Years Considered
    Figure 5. Global Gestational Trophoblastic Disease Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Gestational Trophoblastic Disease Revenue in 2023
    Figure 7. Gestational Trophoblastic Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Chemotherapy Picture
    Figure 9. Surgery Picture
    Figure 10. Radiation Therapy Picture
    Figure 11. Others Picture
    Figure 12. Global Gestational Trophoblastic Disease Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 13. Global Gestational Trophoblastic Disease Sales Value Market Share by Type, 2023 & 2030
    Figure 14. Product Picture of Hospitals
    Figure 15. Product Picture of Clinics
    Figure 16. Product Picture of Cancer Research Institutes
    Figure 17. Product Picture of Others
    Figure 18. Global Gestational Trophoblastic Disease Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 19. Global Gestational Trophoblastic Disease Sales Value Market Share by Application, 2023 & 2030
    Figure 20. North America Gestational Trophoblastic Disease Sales Value (2019-2030) & (US$ Million)
    Figure 21. North America Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
    Figure 22. Europe Gestational Trophoblastic Disease Sales Value (2019-2030) & (US$ Million)
    Figure 23. Europe Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
    Figure 24. Asia Pacific Gestational Trophoblastic Disease Sales Value (2019-2030) & (US$ Million)
    Figure 25. Asia Pacific Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
    Figure 26. South America Gestational Trophoblastic Disease Sales Value (2019-2030) & (US$ Million)
    Figure 27. South America Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
    Figure 28. Middle East & Africa Gestational Trophoblastic Disease Sales Value (2019-2030) & (US$ Million)
    Figure 29. Middle East & Africa Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
    Figure 30. Key Countries/Regions Gestational Trophoblastic Disease Sales Value (%), (2019-2030)
    Figure 31. United States Gestational Trophoblastic Disease Sales Value, (2019-2030) & (US$ Million)
    Figure 32. United States Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
    Figure 33. United States Gestational Trophoblastic Disease Sales Value by Application (%), 2023 VS 2030
    Figure 34. Europe Gestational Trophoblastic Disease Sales Value, (2019-2030) & (US$ Million)
    Figure 35. Europe Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
    Figure 36. Europe Gestational Trophoblastic Disease Sales Value by Application (%), 2023 VS 2030
    Figure 37. China Gestational Trophoblastic Disease Sales Value, (2019-2030) & (US$ Million)
    Figure 38. China Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
    Figure 39. China Gestational Trophoblastic Disease Sales Value by Application (%), 2023 VS 2030
    Figure 40. Japan Gestational Trophoblastic Disease Sales Value, (2019-2030) & (US$ Million)
    Figure 41. Japan Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
    Figure 42. Japan Gestational Trophoblastic Disease Sales Value by Application (%), 2023 VS 2030
    Figure 43. South Korea Gestational Trophoblastic Disease Sales Value, (2019-2030) & (US$ Million)
    Figure 44. South Korea Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
    Figure 45. South Korea Gestational Trophoblastic Disease Sales Value by Application (%), 2023 VS 2030
    Figure 46. Southeast Asia Gestational Trophoblastic Disease Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Southeast Asia Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
    Figure 48. Southeast Asia Gestational Trophoblastic Disease Sales Value by Application (%), 2023 VS 2030
    Figure 49. India Gestational Trophoblastic Disease Sales Value, (2019-2030) & (US$ Million)
    Figure 50. India Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
    Figure 51. India Gestational Trophoblastic Disease Sales Value by Application (%), 2023 VS 2030
    Figure 52. Gestational Trophoblastic Disease Industrial Chain
    Figure 53. Gestational Trophoblastic Disease Manufacturing Cost Structure
    Figure 54. Channels of Distribution (Direct Sales, and Distribution)
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS